Hyperexpression of HER2/neu and/or amplification of ERBB2 isobserved in 15–20% of BC cases; they are considered an unfavorableprognostic factor and are characterized by an aggressive disease course, aswell as low rates of overall and disease-free survival [18, 19]. Here, ERBB2 is linked to breast cancer.